Setting realistic goals essential for satisfaction
By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Whats next Glucagon-like peptide 1 (GLP-1) agonists, used to treat Type 2 diabetes and obesity, have been a success story in the industry, with Novo Nordisk riding a blockbuster wave with Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity, and Eli Lilly and Company also riding the wave with Mounjaro/Zepbound (tirzepatide), a dual-activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 medication, respectively for treating Type 2 diabetes and obesity
In fact, many report that it feels like a switch has been flipped
Awuchi CG (2023) Plants, phytochemicals, and natural practices in complementary and alternative system of medicine for treatment of central nervous system disorders
Certain people do not digest sulfur-rich foods well, are not able to get enough glutathione precursors from diet alone